Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients

Authors

  • Ahmed Abdel Hadi Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Ali El Hindawi Faculty of Medicine Cairo University, Cairo
  • Amal Hareedy Faculty of Medicine Cairo University, Cairo
  • Heba Khalil Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Ranya Al Ashiry Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Shady Elia Faculty of Medicine Cairo University, Cairo
  • Ahmed Sadek Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Mona Magdy Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Rafatt Atta Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Amgad Anas Theodor Bilharz Research Institute, Imbaba, Giza, Cairo
  • Hisham Bakr General Surgery & Surgical Oncology, Ain Shams University, Cairo
  • Olfat Hammam Theodor Bilharz Research Institute, Imbaba, Giza, Cairo

DOI:

https://doi.org/10.3889/oamjms.2016.104

Keywords:

Her2/neu, Gastric carcinoma, immunohistochemistry, fluorescence in situ hybridization, dysplasia

Abstract

AIM: Amplification of the Her2/neu gene and overexpression of the Her2/neu protein in gastric carcinoma (GC) is a golden criterion for target therapy with trastuzumab (Herceptin). We aim to evaluate the immunohistochemical protein expression and amplification of the oncogene Her2/neu by FISH technique in the epithelial gastric carcinoma and to compare their association with different clinicopathologic parameters aiming at identifying positive cases that may benefit from targeted therapy.

MATERIALS AND METHODS: This study was done on eighty-five tumour tissue samples from patients with GC as well as thirty non-malignant lesions (Gastritis, intestinal metaplasia, adenoma with low-grade dysplasia, adenoma with high-grade dysplasia). All were immunohistochemically stained with Her2/neu antibody.

RESULTS: All equivocal and some selected GC cases were submitted for FISH technique to detect Her2/neu gene amplification. By immunohistochemistry twenty-three cases (27%) were defined as positive for Her2/neu gene amplification and/or protein overexpression. The levels of Her2/neu positive (3+), Her2/neu equivocal (2+) and Her2/neu negative (1+/0) were measurable in 14.2%, 32.9% and 52.9% of the samples, respectively. FISH showed that Her2/neu gene was amplified in 22 cases, 10 Her2/neu positive (3+), 11 (39.3%) Her2/neu equivocal (2+) and 1 Her2/neu negative (1+) cases with IHC staining those who can benefit from anti Her2/neu target therapy. Her2/neu was overexpressed positivity (3+) more in intestinal type and mixed carcinoma, and moderately differentiated tumours. None of gastritis, intestinal metaplasia or adenoma with low-grade dysplasia cases showed positivity for Her2/neu (3+). The Her2/neu positivity (3+) was associated with both adenocarcinoma cases and high-grade dysplasia (P = 0.002).

CONCLUSIONS: The results highlight the necessity of FISH test for further categorization when gastric cancer cases are equivocal (2+) by IHC to determine eligibility for the targeted therapy. Stepwise increase in the expression of Her2/neu was seen in low-grade dysplasia, high-grade dysplasia and carcinoma cases implying its role in cancer evolution. Overexpression of Her 2/neu in GC patients can be promising in selecting those who can get beneï¬t from anti-Her2/neu target therapy.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Venkateshwari A, Krishnaveni D, Venugopal S, et al. Helicobacter pylori infection in relation to gastric cancer progression. Indian J Cancer. 2011; 48:94-8. http://dx.doi.org/10.4103/0019-509X.75840 PMid:21248438 DOI: https://doi.org/10.4103/0019-509X.75840

Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. Available from: http://globocan.iarc.fr/Pages/references.aspx. http://globocan.iarc.fr/Pages/Map.aspx. PMCid:PMC3865341

The National Cancer Registry Program of Egypt (NCRPE). Reports and Statistics: Aswan, Damietta & El-Minia [Internet]. [cited 2014 Feb 22]. Available from: http://www.Cancerregistry.gov.eg/oops.aspx? aspxerrorpath=/publications.aspx

Alieldin N. NCI hospital-based registry 2002–2010 [Internet]. [cited 2014 Feb 23]. Available from: http://nci.cu.edu.eg/App_Files/registry/NCI_registry% 202002-2010.pdf

Lastraioli E, Romoli MR, Arcangeli A. Immunohistochemical biomarkers in gastric cancer research and management. Int J Surg Oncol. 2012;2012:868645. http://dx.doi.org/10.1155/2012/868645 DOI: https://doi.org/10.1155/2012/868645

Moelans CB, de Weger RA, van Diest PJ. Multiplex ligation-dependent probe amplification to detect HER2 amplification in breast cancer: new insights in optimal cut-off value. Cell Oncol. 2010;32(4):311-2. PMid:20442492 PMCid:PMC4619176 DOI: https://doi.org/10.1155/2010/706235

Popescu NC, King CR, Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. Genomics. 1989; 4:362-6. http://dx.doi.org/10.1016/0888-7543(89)90343-1 DOI: https://doi.org/10.1016/0888-7543(89)90343-1

Jørgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology. 2010;78(1):26-33. http://dx.doi.org/10.1159/000288295 PMid:20185938 DOI: https://doi.org/10.1159/000288295

Hofmann M, Stoss O, Shi D, Büttner R, van de Vijver M, Kim W, Ochiai A, Rüschoff J, Henkel T. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797-805. http://dx.doi.org/10.1111/j.1365-2559.2008.03028.x PMid:18422971 DOI: https://doi.org/10.1111/j.1365-2559.2008.03028.x

Laurén P. The two histologic main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand. 1965; 64: 31-49. PMid:14320675 DOI: https://doi.org/10.1111/apm.1965.64.1.31

Edge SB, Byrd DR, Compton CC, et al. Esophagus and Esophagogastric Junction, Stomach. In: AJCC cancer staging manual, 7th ed. Chapter 10 & 11, pp. 103-126. Edited by: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Published by: Springer New York Dordrecht Heidelberg London, 2011.

Lauwers GY, Carneiro F, Graham DY, et al. : Tumours of the Stomach. In: World Health Organization Classification of Tumours of the Digestive System. 4th ed. Chapter 4, pp. 45-79. Edited by: Bosman FT, Carneiro F, Hruban RH, Theise ND. Published by: IARC press, Lyon, 2010.

Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ et al. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013; 24(7):1754-61. http://dx.doi.org/10.1093/annonc/mdt106 PMid:23524864 PMCid:PMC3690906 DOI: https://doi.org/10.1093/annonc/mdt106

Marano L, Roviello F. The distinctive nature of HER2-positive gastric cancers. Eur J Surg Oncol. 2015; 41:271-3. http://dx.doi.org/10.1016/j.ejso.2014.12.007 PMid:25605551 DOI: https://doi.org/10.1016/j.ejso.2014.12.007

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, ToGA Trial. Trastuzumab Investigators. in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, openlabel, randomised controlled trial. Lancet. 2010;376(9742):687-97. http://dx.doi.org/10.1016/S0140-6736(10)61121-X DOI: https://doi.org/10.1016/S0140-6736(10)61121-X

Zeeneldin AA, Ramadan H, El Gammal MM, Saber MM , Elgamal D , Sherisher MA. Gastric carcinoma at Tanta Cancer Center: a comparative retrospective clinico-pathological study of the elderly versus the non-elderly. J Egypt Natl Canc Inst. 2014; 26:127-137. http://dx.doi.org/10.1016/j.jnci.2014.04.002 PMid:25150128 DOI: https://doi.org/10.1016/j.jnci.2014.04.002

Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Lipatov O. Pathological features of advanced gastric cancer (GC): Relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27:15s (suppl: abst.4556). DOI: https://doi.org/10.1200/jco.2009.27.15_suppl.4556

Chen XZ, Zhang WH, Yao WQ, Liu JP, Zhou ZG, Chen ZX. Immunohistochemical HER2 expression not associated with clinico pathological characteristics of stage I-III gastric cancer patients. Hepatogastroenterology. 2015;61(134):1817-21.

Otsu H, Oki E, Ikawa Yoshida A, Kawano H, Ando K, Ida S. Correlation of HER2 expression with clinicopathological characteristics and prognosis in resectable gastric cancer. Anticancer Res. 2015; 35(4):2441-6. PMid:25862912

Gu J, Zheng L, Wang Y, Zhu M, Wang Q, Li X. Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis. Tumour Biol. 2014;35(6):5315-21. http://dx.doi.org/10.1007/s13277-014-1693-7 PMid:24557541 DOI: https://doi.org/10.1007/s13277-014-1693-7

Jácome AA, Wohnrath DR, Scapulatempo Neto C, Carneseca EC, Serrano SV, Viana LS. Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long term survivors. Gastric Cancer. 2014; 17(1):76-86. http://dx.doi.org/10.1007/s10120-013-0236-z PMid:23455716 PMCid:PMC3889290 DOI: https://doi.org/10.1007/s10120-013-0236-z

De Carli DM, Rocha MP, Antunes LC, Fagundes RB. Immuno histochemical expression of HER2 in adenocarcinoma of the stomach. Arq Gastroenterol. 2015;52(2):152-5. http://dx.doi.org/10.1590/S0004-28032015000200015 PMid:26039836 DOI: https://doi.org/10.1590/S0004-28032015000200015

Koopman T, Smits MM, Louwen M, Hage M, Boot H, Imholz AL. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol. 2015; 141(8):1343-51. http://dx.doi.org/10.1007/s00432-014-1900-3 PMid:25544671 DOI: https://doi.org/10.1007/s00432-014-1900-3

Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junctionadenocarcinoma in a Chinese population. Diagn Pathol. 2013; 8:76. http://dx.doi.org/10.1186/1746-1596-8-76 PMid:23656792 PMCid:PMC3655831

Rajagopal I, Niveditha S R, Sahadev R, Nagappa KP, Rajendra GS. HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adeno-carcinomas J Clin Diagn Res. 2015; 9(3): EC06–EC10. PMid:25954623 PMCid:PMC4413071 DOI: https://doi.org/10.7860/JCDR/2015/12581.5630

Yan YS, Ying Hu, Jian-Gao Fan, Guo-Quan Tao, Yong-Ming Lu, Xu Cai. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma .World J Gastroenterol. 2011; 17(11): 1501–1506. http://dx.doi.org/10.3748/wjg.v17.i11.1501 PMid:21472111 PMCid:PMC3070026 DOI: https://doi.org/10.3748/wjg.v17.i11.1501

Kataoka Y, Okabe H, Yoshizawa A, Minamiguchi S, Yoshimura K, Haga H, Sakai Y. HER2 expression and its clinicopathological features in resectable gastric cancer. Gastric Cancer. 2013;16(1):84-93. http://dx.doi.org/10.1007/s10120-012-0150-9 PMid:22410801 DOI: https://doi.org/10.1007/s10120-012-0150-9

Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR. HER2 expression in gastric and gastroesophageal junction adeno carcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012; 20(1):13-24. http://dx.doi.org/10.1097/PAI.0b013e31821c821c PMid:21617522 DOI: https://doi.org/10.1097/PAI.0b013e31821c821c

Liang JW, Zhang JJ, Zhang T, Zheng ZC. Clinico pathological and prognostic significance of HER2 overexpression in gastric cancer: a meta-analysis of the literature. Tumour Biol. 2014; 35(5):4849-58. http://dx.doi.org/10.1007/s13277-014-1636-3 PMid:24449506 DOI: https://doi.org/10.1007/s13277-014-1636-3

Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013 ;8:76. http://dx.doi.org/10.1186/1746-1596-8-76 PMid:23656792 PMCid:PMC3655831 DOI: https://doi.org/10.1186/1746-1596-8-76

He C, Bian XY, Ni XZ, Shen DP, Shen YY, Liu H. Correlation of human epidermal growth factor receptor 2 expression with clinic pathological characteristicsand prognosis in gastric cancer. World J Gastro Enterol. 2013;19(14):2171-8. http://dx.doi.org/10.3748/wjg.v19.i14.2171 PMid:23599643 PMCid:PMC3627881 DOI: https://doi.org/10.3748/wjg.v19.i14.2171

Zhang X, Qu J, Sun G, Yang J, Yang Y. Simultaneous detection of expression and gene mutations of HER2/neu in Chinese patients with gastric cancer. Oncol Lett. 2010;1(3):559-563. PMid:22966343 PMCid:PMC3436403 DOI: https://doi.org/10.3892/ol_00000099

Wang YL, Sheu BS, Yang HB, Lin PW, Chang YC. Overexpression of c-erb-B2 proteins in tumor and non-tumor parts of gastric adenocarcinoma-emphasis on its relation to H. pylori infection and clinic histological characteristics. Hepatogastroenterology. 2002;49(46):1172-6. PMid:12143229

Slesak B, Harlozinska A, Porebska I, Bojarowski T, Lapinska J, Rzeszutko M, Wojnar A. Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis. Anticancer Res. 1998; 18(4A):2727-32. PMid:9703936

Rosai J: Gastrointestinal Tract, Stomach . In: Rosai and Ackerman's Surgical Pathology, 10th ed. Chapter 11, pp. 615-672. Edited by: Rosai J. Published by: Elsevier, 2011.

Hu Y, Bandla S, Godfrey TE, Tan D, Luketich JD, Pennathur A. HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma. Mod Pathol. 2011 ;24(7):899-907. http://dx.doi.org/10.1038/modpathol.2011.47 PMid:21460800 PMCid:PMC3138485 DOI: https://doi.org/10.1038/modpathol.2011.47

Fassan M, Mastracci L, Grillo F, Zagonel V, Bruno S, Battaglia G, Pitto F, Nitti D, Celiento T, Zaninotto G, Fiocca R, Rugge M. Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology. 2012;61(5):769-76. http://dx.doi.org/10.1111/j.1365-2559.2012.04272.x PMid:22882541 DOI: https://doi.org/10.1111/j.1365-2559.2012.04272.x

Published

2016-09-14

How to Cite

1.
Abdel Hadi A, El Hindawi A, Hareedy A, Khalil H, Al Ashiry R, Elia S, Sadek A, Magdy M, Atta R, Anas A, Bakr H, Hammam O. Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients. Open Access Maced J Med Sci [Internet]. 2016 Sep. 14 [cited 2024 Mar. 29];4(4):535-42. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2016.104

Issue

Section

A - Basic Science

Most read articles by the same author(s)